We remain committed to contributing to the fight against COVID-19 and protecting and supporting our people, as well as our valued customers, patients and partners.
Over the past several weeks, we have mobilized across the company to respond to the pandemic, focusing on our people, business continuity and providing solutions to support the global response. We are actively exploring ways to help with our science and expertise, and managing our global supply chains to support those who depend on our products.
Supporting your needs
As COVID-related guidance and restrictions continue to evolve across the country, we are operating with a high degree of care as the virus remains a very serious public health threat. At the same time, we want to ensure we are continuing to provide you with the information and support you need in caring for your patients.
Our field teams have the opportunity to return to in-person customer visits in a phased manner, taking into account employee safety, customer needs and business continuity. In all cases, we will make these decisions with careful consideration subject to guidance from local authorities and based on restrictions being applied in clinical offices and health care centers. Our teams will also continue to use virtual tools to provide support and ensure access to information and resources.
Helping patients access care
For decades, we have helped patients who need financial assistance with access to our medicines and vaccines. Our commitment to help patients in this time of need continues.
Patients and healthcare professionals can find more information about specific resources that may help them, including charitable products, patient assistance programs, coupon and co-pay programs and reimbursement support at GSKforyou.com.
Contributing to the fight against COVID-19
GSK is harnessing science, technology and our portfolio to support development of medicine and vaccines for the prevention and treatment of COVID-19.
As the world’s largest vaccines maker, we’re working with companies and research groups across the world on promising COVID-19 vaccine candidates through the use of our innovative vaccine adjuvant technology. The use of an adjuvant is of particular importance in a pandemic since it may reduce the amount of vaccine protein required per dose, allowing more vaccine doses to be produced.
We recently announced that GSK joined forces with Sanofi, bringing together two of the world’s largest vaccine companies in collaboration to fight COVID-19. We expect a vaccine candidate to enter clinical trials in the second half of 2020 and, if successful and subject to regulatory considerations, aim to complete the development required for availability by the second half of 2021.
GSK is also donating $10 million to The COVID-19 Solidarity Response Fund, created by the UN Foundation and World Health Organization (WHO), to support WHO and partners to prevent, detect, and manage the pandemic, particularly where the needs are the greatest.
Visit our COVID-19 Resource Center to learn more about our actions to support the global response to COVID-19.
Ensuring medicine supply
Central to our efforts to tackle COVID-19, we are focused on managing our global supply chains to support patients and consumers who depend on our products.
We are closely monitoring all parts of our supply chains and developing contingency plans to help us respond to the situation. We have taken a number of measures to support supply of our products, including increasing manufacturing to produce some high demand respiratory products around the clock, using the fastest methods available to transport products from our facilities, and actively managing supply.
Answering your questions
Please contact your field representative, or if you do not have a representative, call 1-888-825-5249 or visit gskpro.com with any questions about GSK products.
For questions about ongoing clinical studies, click here to learn more about guidance for clinical trial investigators. GSK remains supportive of enrolling new patients at this time, provided that investigators are confident they will be able to conduct the protocol specified safety and efficacy monitoring required for each study.
We continue to monitor the situation closely and will take further actions to develop our response to the pandemic.
Patient focus is one of our core values, and I am proud of our team and their commitment to patients during these challenging times. More than ever, know we remain absolutely committed to partnering with you to provide support and help patients who need care.
Sincerely,
Maya Martinez-Davis
President, U.S. Pharmaceuticals
GSK U.S. Country Lead for COVID-19 Issues Management Team
